In conclusions, our research highlights PYGB as a potential therapeutic target in GBM proposing 1g as a lead compound for developing a new class of simplified analogs active as anticancer drugs for glioblastoma, keeping unchanged its ability to cross the blood–brain barrier. This evidence concerns the gene PYGB and glioblastoma.